Barclays’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History
Bought
Maintained
Sold
Other funds holding IDNA
WBG
WAP
Barclays's IDNA Position: Q4 2021 in Review
Barclays sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q4 2021, closing a stake of 798 shares — an estimated $40K sold.
Barclays first reported a position in IDNA in Q3 2021 and held it in 1 quarter. The position peaked at $40K in Q3 2021. 103 funds tracked by Wall St. Rank hold IDNA as of Q4 2021.
- Barclays reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q4 2021 after selling out during the quarter.
- Barclays sold 798 iShares Genomics Immunology and Healthcare ETF shares in Q4 2021, an estimated $40K.
- Barclays first reported a position in iShares Genomics Immunology and Healthcare ETF in Q3 2021 and held it in 1 quarter.
- Barclays's iShares Genomics Immunology and Healthcare ETF position peaked at $40K in Q3 2021.
- 103 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q4 2021.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.